Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Drugs Used In the Treatment of Congestive Heart Failure
Prototype drugs to know for treatment of heart failure <ul><li>Inotropes   – digoxin, inamrinone,dobutamine, dopamine  </l...
 
 
DEFINITION “ The situation when the heart is  incapable of maintaining a cardiac  output adequate to accommodate metabolic...
 
 
EVOLUTION OF  CLINICAL STAGES NORMAL Asymptomatic  LV Dysfunction Compensated CHF Decompensated CHF No symptoms Normal exe...
 
 
 
 
 
 
 
 
 
 
 
 
DIGOXIN   NEUROHORMONAL   EFFECTS   Plasma   Noradrenaline   Peripheral nervous system activity   RAAS activity    Vagal  ...
 
 
DIGOXIN TOXICITY CARDIAC MANIFESTATIONS ARRHYTHMIAS : -  Ventricular (PVCs, VT, VF) -  Supraventricular (PACs, SVT) BLOCKS...
 
 
% WORSENING  OF CHF p = 0.001 DIGOXIN: 0.125 - 0.5 mg /d  (0.7 - 2.0 ng/ml) EF < 35% Class I-III (digoxin+diuretic+ACEI) A...
Placebo n=3403 DIGOXIN n=3397 48 0 12 24 36 OVERALL MORTALITY  % DIG N Engl J Med 1997;336:525 Months p = 0.8 50 40 30 20 ...
 
Upcoming SlideShare
Loading in …5
×

Digitalis Lecture

5,284 views

Published on

Digitalis Lecture

Published in: Health & Medicine
  • Be the first to comment

Digitalis Lecture

  1. 1. Drugs Used In the Treatment of Congestive Heart Failure
  2. 2. Prototype drugs to know for treatment of heart failure <ul><li>Inotropes – digoxin, inamrinone,dobutamine, dopamine </li></ul><ul><li>Diuretics - hydrochlorothiazide, furosemide, amiloride, spironolactone </li></ul><ul><li>ACE inhibitors – captopril, enalapril,lisinopril </li></ul><ul><li>AII receptor blockers -valsartan,losartan </li></ul><ul><li>Sympatholytics – propranolol, carvedilol </li></ul><ul><li>Vasodilators – glyceryl trinitrate, hydralazine, sodium nitroprusside </li></ul>
  3. 5. DEFINITION “ The situation when the heart is incapable of maintaining a cardiac output adequate to accommodate metabolic requirements and the venous return. &quot; E. Braunwald
  4. 8. EVOLUTION OF CLINICAL STAGES NORMAL Asymptomatic LV Dysfunction Compensated CHF Decompensated CHF No symptoms Normal exercise Normal LV fxn No symptoms Normal exercise Abnormal LV fxn No symptoms Exercise Abnormal LV fxn Symptoms Exercise Abnormal LV fxn Refractory CHF Symptoms not controlled with treatment Chronic Congestive Heart Failure
  5. 21. DIGOXIN NEUROHORMONAL EFFECTS Plasma Noradrenaline Peripheral nervous system activity RAAS activity Vagal tone Normalizes arterial baroreceptors
  6. 24. DIGOXIN TOXICITY CARDIAC MANIFESTATIONS ARRHYTHMIAS : - Ventricular (PVCs, VT, VF) - Supraventricular (PACs, SVT) BLOCKS: - S-A and A-V blocks CHF EXACERBATION
  7. 27. % WORSENING OF CHF p = 0.001 DIGOXIN: 0.125 - 0.5 mg /d (0.7 - 2.0 ng/ml) EF < 35% Class I-III (digoxin+diuretic+ACEI) Also significantly decreased exercise time and LVEF. DIGOXIN EFFECT ON CHF PROGRESSION RADIANCE N Engl J Med 1993;329:1 Placebo n=93 DIGOXIN Withdrawal DIGOXIN n=85 30 10 0 20 100 80 20 0 40 60 Days
  8. 28. Placebo n=3403 DIGOXIN n=3397 48 0 12 24 36 OVERALL MORTALITY % DIG N Engl J Med 1997;336:525 Months p = 0.8 50 40 30 20 10 0

×